Boston Scientific Picks Up Pancreatic Stent Maker Xlumena
This article was originally published in The Gray Sheet
In the $62.5 million-plus-milestone deal Boston Scientific gets Xlumena's Axios and Hot Axios stent and delivery systems for endoscopic ultrasound-guided transluminal drainage of symptomatic pancreatic pseudocysts. The products fit alongside Boston's Expect endoscopic ultrasound aspiration needles.
You may also be interested in...
Boston Scientific will pay about $230m for 64% of Korea-based MI Tech, which developed the Hanarostent line of conformable, self-expanding metal stents for endoscopic and urologic applications.
Siemens teams with Pfizer on companion Dx. XLumena gains pancreatic stent approval. AtriCure acquires Estech. More news.
Takeda’s TAK-721 is back, ARS Pharma will be back soon to appeal neffy complete response letter, US FDA’s Project Renewal brings Temodar labeling in current day, and more highlights from the Pink Sheet’s US FDA Performance Tracker.